Cantabio Pharmaceuticals Receives Additional Grant from The Michael J. Fox Foundation for Testing Its Novel Redox DJ-1 Protein-based ELISA Platform for the Diagnosis of Parkinson's Disease
Summary
The project will apply Cantabios novel Redox DJ-1 ELISA platform to quantify the concentration of DJ-1 in distinct oxidized states of Cys106 through a blood test, and ultimately correlate these with a patients risk of developing sporadic PD, and/or to diagnose in the early stages of the disease before motor symptoms can be detected. The ability to detect this pre-symptomatic disease phase is believed to be crucial for R&D efforts to develop therapeutics for preventing or treating PD. "MJFF greatly values research targeting the biology of Parkinsons disease and leveraging that insight to develop diagnostic tools. Fox Foundation in our efforts to apply our novel Redox DJ-1 ELISA platform to develop a DJ-1 based biomarker for Parkinsons, which has the potential to be used for early diagnosis of the disease. Cantabios programs focus on protein systems implicated in neurodegenerative disorders, including Alzheimers and Parkinsons, as well as Diabetic Kidney disease.